Carlsbad, CA – According to filings with the U.S. Securities and Exchange Commission, View Point Medical is raising $17,159,016.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Peter Klemm played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About View Point Medical

View Point Medical is a medical device and technology company dedicated to improving surgical outcomes using novel tissue markers that enable effective lesion localization in cancer care. The company’s core technology is SignalMark, an implantable tissue marker platform designed to perform across a broad set of clinical applications and intraoperative scenarios under multiple modes of detection and imaging. View Point’s first product, the SignalMark Lung Marker, the first all in one bioresorbable lung surface marking and localization tool, received FDA clearance in December of 2018. The company is leveraging the SignalMark technology platform to deliver a portfolio of markers and detection devices that simplify the way clinicians mark, track and remove cancer across the ?treatment path.

To learn more about View Point Medical, visit http://www.viewpointmed.com/

Contact:
Peter Klemm, Chief Executive Officer
858-847-9446
https://www.linkedin.com/in/peter-klemm-7864a25b/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved